Chemed Corporation $CHE Shares Sold by Van Berkom & Associates Inc.

Van Berkom & Associates Inc. trimmed its holdings in shares of Chemed Corporation (NYSE:CHE) by 25.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 120,960 shares of the company’s stock after selling 41,849 shares during the quarter. Chemed accounts for about 2.2% of Van Berkom & Associates Inc.’s investment portfolio, making the stock its 26th biggest position. Van Berkom & Associates Inc.’s holdings in Chemed were worth $61,093,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Chemed in the 2nd quarter valued at approximately $691,290,000. First Trust Advisors LP boosted its stake in shares of Chemed by 24.7% during the 1st quarter. First Trust Advisors LP now owns 236,392 shares of the company’s stock valued at $89,295,000 after buying an additional 46,791 shares during the last quarter. Copeland Capital Management LLC grew its position in shares of Chemed by 1.3% during the third quarter. Copeland Capital Management LLC now owns 146,833 shares of the company’s stock worth $74,162,000 after buying an additional 1,826 shares in the last quarter. Bank of America Corp DE acquired a new stake in shares of Chemed during the second quarter worth approximately $48,255,000. Finally, Caisse de depot et placement du Quebec acquired a new stake in shares of Chemed during the second quarter worth approximately $44,309,000. Institutional investors and hedge funds own 95.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Chemed from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 10th. Jefferies Financial Group upgraded shares of Chemed from a “hold” rating to a “buy” rating and increased their price objective for the company from $520.00 to $620.00 in a research note on Wednesday, October 28th. Weiss Ratings raised shares of Chemed from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. UBS Group boosted their target price on shares of Chemed from $650.00 to $675.00 and gave the stock a “buy” rating in a research report on Thursday, October 29th. Finally, Royal Bank Of Canada upped their target price on shares of Chemed from $548.00 to $585.00 and gave the company a “sector perform” rating in a research note on Thursday, October 29th. Three research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Chemed currently has a consensus rating of “Hold” and an average target price of $603.00.

Insider Buying and Selling at Chemed

In other news, CEO Kevin J. Mcnamara sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $537.90, for a total value of $1,075,800.00. Following the transaction, the chief executive officer directly owned 82,220 shares in the company, valued at approximately $44,226,138. This trade represents a 2.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Spencer S. Lee sold 920 shares of Chemed stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $537.17, for a total transaction of $494,196.40. Following the completion of the transaction, the executive vice president directly owned 13,931 shares of the company’s stock, valued at $7,483,315.27. This trade represents a 6.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 9,920 shares of company stock valued at $5,223,056. 3.33% of the stock is owned by insiders.

Chemed Price Performance

Shares of NYSE CHE opened at $538.84 on Tuesday. Chemed Corporation has a twelve month low of $365.20 and a twelve month high of $562.24. The company has a current ratio of 1.11, a quick ratio of 1.08 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $7.02 billion, a price-to-earnings ratio of 23.95, a price-to-earnings-growth ratio of 2.08 and a beta of 0.50. The business has a 50 day simple moving average of $514.76 and a 200-day simple moving average of $465.51.

Chemed (NYSE:CHE) last posted its quarterly earnings results on Tuesday, October 27th. The company reported $6.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.44 by $0.31. Chemed had a return on equity of 35.18% and a net margin of 10.61%. The business had revenue of $690.94 million for the quarter, compared to analyst estimates of $685.04 million. During the same period in the prior year, the company posted $5.27 EPS. The business’s revenue was up 10.6% compared to the same quarter last year. As a group, equities research analysts expect that Chemed Corporation will post 24.05 earnings per share for the current year.

Chemed Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 4th. Shareholders of record on Monday, November 16th will be paid a dividend of $0.70 per share. The ex-dividend date is Monday, November 16th. This represents a $2.80 annualized dividend and a yield of 0.5%. Chemed’s payout ratio is presently 13.40%.

Chemed Company Profile

Chemed Corporation is a U.S.-based company operating through two principal businesses: VITAS Healthcare, which provides hospice and palliative care, and Roto-Rooter, which offers plumbing, drain-cleaning and water-restoration services.

VITAS serves patients with serious illnesses through home-based care and services in hospice facilities and other care settings. Roto-Rooter serves residential and commercial customers with plumbing and drain services, as well as cleanup and restoration following water damage.

Chemed’s businesses operate across the United States.